베타
임상 레이더 AI
임상시험 NCT07489599은(는) Alzheimer's Disease(AD), 경도 인지 장애 (MCI)에 대해 대상자모집전 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요.
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰

A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease 1상 68

대상자모집전
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '임상시험 설명'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT07489599은(는) 치료을(를) 알아보기 위한 연구입니다. 이 연구는 Alzheimer's Disease(AD), 경도 인지 장애 (MCI)에 대해 진행되며, 1상 중재연구으로 현재 상태는 대상자모집전입니다. 참여 신청은 2026년 3월 1일부터 가능하며, 68명의 참여자를 모집할 예정입니다. Qilu Pharmaceutical Co., Ltd.이(가) 진행하는 이 연구는 2027년 3월 1일까지 진행될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2026년 3월 24일에 갱신되었습니다.
간단한 개요
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of QLH2405 injection in healthy participants and participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild Alzheimer's disease.
공식 제목

A Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single, Subcutaneous, Ascending Doses of QLH2405 Injection in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

질환명
Alzheimer's Disease(AD)경도 인지 장애 (MCI)
기타 연구 식별자
  • QLH2405-101
NCT 번호
실제 연구 시작일
2026-03
최신 업데이트 게시
2026-03-24
예상 연구 완료일
2027-03
계획된 등록 인원
68
연구종류
중재연구
단계/상
1상
상태
대상자모집전
주요 목적
치료
설계 할당
무작위배정
중재 모델
평행설계
맹검 (마스킹)
사중맹검
시험군 / 개입
참가자 그룹/시험군개입/치료
실험적Part A Cohort 1: Dose level 1 of QLH2405
Participants will receive a single dose of QLH2405 at dose level 1.
QLH2405
QLH2405 will be administered as specified in each treatment arm.
실험적Part A Cohort 2: Dose level 2 of QLH2405
Participants will receive a single dose of QLH2405 at dose level 2.
QLH2405
QLH2405 will be administered as specified in each treatment arm.
위약 대조군Part A Cohort 2: Placebo
Participants will receive a single dose of matching placebo to level 2.
위약
QLH2405-matching placebo will be administered as specified in each treatment arm.
실험적Part A Cohort 3: Dose level 3 of QLH2405
Participants will receive a single dose of QLH2405 at dose level 3.
QLH2405
QLH2405 will be administered as specified in each treatment arm.
위약 대조군Part A Cohort 3: Placebo
Participants will receive a single dose of matching placebo to level 3.
위약
QLH2405-matching placebo will be administered as specified in each treatment arm.
실험적Part A Cohort 4: Dose level 4 of QLH2405
Participants will receive a single dose of QLH2405 at dose level 4.
QLH2405
QLH2405 will be administered as specified in each treatment arm.
위약 대조군Part A Cohort 4: Placebo
Participants will receive a single dose of matching placebo to level 4.
위약
QLH2405-matching placebo will be administered as specified in each treatment arm.
실험적Part A Cohort 5: Dose level 5 of QLH2405
Participants will receive a single dose of QLH2405 at dose level 5.
QLH2405
QLH2405 will be administered as specified in each treatment arm.
위약 대조군Part A Cohort 5: Placebo
Participants will receive a single dose of matching placebo to level 5.
위약
QLH2405-matching placebo will be administered as specified in each treatment arm.
실험적Part A Cohort 6: Dose level 6 of QLH2405
Participants will receive a single dose of QLH2405 at dose level 6.
QLH2405
QLH2405 will be administered as specified in each treatment arm.
위약 대조군Part A Cohort 6: Placebo
Participants will receive a single dose of matching placebo to level 6.
위약
QLH2405-matching placebo will be administered as specified in each treatment arm.
실험적Part B Cohort 1: Dose level 3 of QLH2405
Participants will receive a single dose of QLH2405 at dose level 3.
QLH2405
QLH2405 will be administered as specified in each treatment arm.
위약 대조군Part B Cohort 1: Placebo
Participants will receive a single dose of matching placebo to level 3.
위약
QLH2405-matching placebo will be administered as specified in each treatment arm.
실험적Part B Cohort 2: Dose level 4 of QLH2405
Participants will receive a single dose of QLH2405 at dose level 4.
QLH2405
QLH2405 will be administered as specified in each treatment arm.
위약 대조군Part B Cohort 2: Placebo
Participants will receive a single dose of matching placebo to level 4.
위약
QLH2405-matching placebo will be administered as specified in each treatment arm.
실험적Part B Cohort 3: Dose level 5 of QLH2405
Participants will receive a single dose of QLH2405 at dose level 5.
QLH2405
QLH2405 will be administered as specified in each treatment arm.
위약 대조군Part B Cohort 3: Placebo
Participants will receive a single dose of matching placebo to level 5.
위약
QLH2405-matching placebo will be administered as specified in each treatment arm.
주요결과변수
결과변수측정값 설명시간 범위
Adverse Events (AEs)
Percentage of Participants with AEs
Up to approximately 28 weeks
참여 도우미
적격성 기준

연령대
성인, 노인
최소 연령
18 Years
참여 가능한 성별
전체
건강한 참가자 허용
  1. Voluntarily participate and sign the informed consent.
  2. Male or female, aged 18 to 65 years (inclusive).
  3. Healthy status as confirmed by medical evaluation.
  4. Body mass index (BMI) of 19-28 kg/m² (inclusive).
  5. Agree to use effective contraception and have no plans for sperm/egg donation or pregnancy from ICF signing until 9 months post-dose.

Inclusion Criteria for Part B:

  1. Voluntarily participate and sign the informed consent, able to communicate well with the investigator and complete the trial per protocol.
  2. Male or female, aged 50 to 85 years (inclusive).
  3. A diagnosis of mild MCI due to AD or mild AD according to the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria.
  4. Has subjective cognitive and memory decline for ≥6 months.
  5. Confirmation of Alzheimer's disease pathological changes by amyloid PET (Aβ-PET) scan.
  6. Has one (or more) reliable study partner (s)/adult caregiver(s) can accompany the participant to all visits.
  7. Agree to use effective contraception and have no plans for sperm/egg donation or pregnancy from ICF signing until 9 months post-dose.

  1. History of significant diseases, or any existing disease may affect the study or pose an unacceptable risk to the participant.
  2. Positive for HBsAg, HIV-Ab, Treponema pallidum antibody, or HCV-Ab.
  3. History of blood donation, significant blood loss (total volume ≥400 mL), or blood transfusion within 3 months prior to screening.
  4. History of alcohol abuse within 1 year prior to screening; or positive alcohol breath test.
  5. History of drug abuse and/or substance abuse; or positive drug screening.
  6. Participation in any drug or medical device clinical trial within 3 months prior to screening.
  7. Pregnant or lactating women, or women of childbearing potential with a positiveβ-hCG test.
  8. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.

Exclusion Criteria for Part B:

  1. Cognitive impairment or dementia caused by any disease other than AD.
  2. History of stroke within 6 months prior to screening, or imaging evidence of clinically significant central nervous system diseases.
  3. History of epileptic seizures or epileptiform abnormalities on EEG within 6 months prior to screening.
  4. Unstable or severe diseases within 6 months prior to screening that, in the investigator's judgment, make the participant unsuitable for study participation.
  5. eGFR <60 mL/min/1.73 m².
  6. AST or ALT >3 × upper limit of normal (ULN), or total bilirubin >2 × ULN.
  7. Current use or anticipated need during the study period for any medication prohibited by the study protocol.
  8. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.
Qilu Pharmaceutical Co., Ltd. logoQilu Pharmaceutical Co., Ltd.
연구 대표 연락처
연락처: Fangyi Wang, Bachelor, +86-18266419923, [email protected]
시험기관의 위치 정보가 없습니다.